Skip to main content
Digital Recording

MDMA-Assisted Therapy in the Treatment of Posttraumatic Stress Disorder

Average Rating:
Ingmar Gorman, PhD
1 Hour 04 Minutes
Audio and Video
Jul 27, 2022
Product Code:
Media Type:
Digital Recording
Never expires.


In the first ever phase 3 trial of MDMA for Posttraumatic Stress Disorder (PTSD), it was reported that 67% of the group who received MDMA, compared to 32% of the group who received placebo, no longer qualified for a PTSD diagnosis after three MDMA treatment sessions. Now, a second Phase 3 clinical trial is nearing completion with a possibility of MDMA becoming an available treatment in the near future. The aim of this recording is to prepare clinicians with an understanding of MDMA-assisted psychotherapy for PTSD in light of this eventuality.


Planning Committee Disclosure - No relevant relationships All members of the PESI, Inc. planning committee have provided disclosures of financial relationships with ineligible organizations and any relevant non-financial relationships prior to planning content for this activity. None of the committee members had relevant financial relationships with ineligible companies or other potentially biasing relationships to disclose to learners. For speaker disclosures, please see the faculty biography.


This online program is worth 1.25 hours CPD.



Ingmar Gorman, PhD's Profile

Ingmar Gorman, PhD Related seminars and products

Dr. Ingmar Gorman is a co-founder of Fluence, a psychedelic education company training mental health providers in psychedelic treatments. As a psychologist, he shares his expertise in empirically supported psychedelic treatments with his clients and trainees alike. Dr. Gorman received his clinical training in New York City at the New School for Social Research, Mount Sinai Beth Israel Hospital, Columbia University, and Bellevue Hospital. He completed his NIH postdoctoral fellowship at New York University. He simultaneously served as site co-principal investigator on an FDA approved Phase 3 clinical trial of MDMA-assisted Psychotherapy for Post-Traumatic Stress Disorder and is currently a study therapist and supervisor on the same study. He is co-author on a Nature Medicine paper reporting the results of the first Phase 3 clinical trial of MDMA-assisted therapy for PTSD. Dr. Gorman has also published on the topics of classic psychedelics, ketamine, and Psychedelic Harm Reduction and Integration.

Speaker Disclosures:
Financial: Dr. Ingmar Gorman is the co-founder and CEO of Fluence International Inc., the lead scientific advisor for Journey Clinical, and receives grants from Beckley Psytech . He receives royalties as a published author. Dr. Gorman receives a speaking honorarium from Psychotherapy Networker and PESI, Inc.
Non-financial: Dr. Ingmar Gorman has no relevant non-financial relationships.


  1. Organize some of the most recent research into MDMA-assisted therapy for PTSD.
  2. Examine the psychological rationale for MDMA's potential therapeutic effect in Posttraumatic Stress Disorder.
  3. Utilize best practices in sharing basic information about MDMA-assisted therapy with clients. 
  4. Formulate strategies for discussing MDMA-assisted therapy from a destigmatized perspective.
  5. Evaluate the potential benefits and limitations of our current scientific understanding. 


  • What is MDMA-assisted therapy? 
  • How is it used for PTSD? 
  • Theorized mechanisms of action 
  • How to discuss MDMA in your practice today 

Target Audience

  • Counsellors
  • Marriage & Family Therapists
  • Nurses
  • Nurse Practitioners
  • Physicians
  • Psychologists
  • Social Workers
  • Other Behavioral Health Professionals



Overall:      4.9

Total Reviews: 2195

Satisfaction Guarantee
Your satisfaction is our goal and our guarantee. Concerns should be addressed to or call 01235847393.

Please wait ...

Back to Top